SG11201908528UA - Novel pd-l1 targeting dna vaccine for cancer immunotherapy - Google Patents

Novel pd-l1 targeting dna vaccine for cancer immunotherapy

Info

Publication number
SG11201908528UA
SG11201908528UA SG11201908528UA SG11201908528UA SG 11201908528U A SG11201908528U A SG 11201908528UA SG 11201908528U A SG11201908528U A SG 11201908528UA SG 11201908528U A SG11201908528U A SG 11201908528UA
Authority
SG
Singapore
Prior art keywords
international
pct
novel
salmonella
english
Prior art date
Application number
Other languages
English (en)
Inventor
Heinz Lubenau
Original Assignee
Vaximm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaximm Ag filed Critical Vaximm Ag
Publication of SG11201908528UA publication Critical patent/SG11201908528UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG11201908528U 2017-03-17 2018-03-16 Novel pd-l1 targeting dna vaccine for cancer immunotherapy SG11201908528UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17161666 2017-03-17
EP17188941 2017-09-01
PCT/EP2018/056721 WO2018167290A1 (en) 2017-03-17 2018-03-16 Novel pd-l1 targeting dna vaccine for cancer immunotherapy

Publications (1)

Publication Number Publication Date
SG11201908528UA true SG11201908528UA (en) 2019-10-30

Family

ID=61627121

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908528U SG11201908528UA (en) 2017-03-17 2018-03-16 Novel pd-l1 targeting dna vaccine for cancer immunotherapy

Country Status (13)

Country Link
US (2) US11357842B2 (ja)
EP (1) EP3595704A1 (ja)
JP (2) JP7247097B2 (ja)
KR (1) KR20190125481A (ja)
CN (1) CN110430893A (ja)
AU (1) AU2018235153A1 (ja)
BR (1) BR112019019251A2 (ja)
CA (1) CA3056807A1 (ja)
IL (1) IL268677A (ja)
MX (1) MX2019011026A (ja)
RU (1) RU2019132253A (ja)
SG (1) SG11201908528UA (ja)
WO (1) WO2018167290A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210042655A (ko) 2019-10-10 2021-04-20 주식회사 엘지화학 히팅 패드 제어 장치
CN114980871A (zh) 2020-01-13 2022-08-30 万科斯蒙股份有限公司 基于沙门氏菌的dna疫苗联合抗生素
CU20200075A7 (es) 2020-10-22 2022-05-11 Ct Ingenieria Genetica Biotecnologia Antígeno quimérico que comprende el dominio extracelular de pd-l1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3399943B2 (ja) * 1991-05-06 2003-04-28 アメリカ合衆国 癌胎児性抗原を発現する組換えウイルスとその使用方法
AU2009288289B2 (en) * 2008-08-25 2012-11-08 Amplimmune, Inc. PD-1 antagonists and methods of use thereof
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CN103917243B (zh) * 2011-10-17 2021-05-11 Io生物技术公司 基于pd-l1的免疫疗法
SG11201500054QA (en) 2012-07-05 2015-03-30 Vaximm Ag Dna vaccine for use in pancreatic cancer patients
HUE038861T2 (hu) * 2013-04-25 2018-12-28 Vaximm Ag Salmonella-alapú vektorok Wilms-tumor WZ1 gént célzó rák immunterápiához
US9637532B2 (en) * 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
AU2014365900B2 (en) * 2013-12-18 2020-04-09 Vaximm Gmbh Novel MSLN targeting DNA vaccine for cancer immunotherapy
US10369205B2 (en) * 2014-01-07 2019-08-06 Babita Agrawal Immunomodulatory compositions and methods of use thereof
DK3310379T3 (da) * 2015-06-18 2019-12-16 Vaximm Ag Vegfr-2-targeterende dna-vaccine til kombinationsterapi
US20180153976A1 (en) * 2015-06-18 2018-06-07 Vaximm Ag Novel cmv pp65 targeting dna vaccine for cancer immunotherapy

Also Published As

Publication number Publication date
RU2019132253A (ru) 2021-04-19
WO2018167290A1 (en) 2018-09-20
IL268677A (en) 2019-10-31
US11357842B2 (en) 2022-06-14
JP7247097B2 (ja) 2023-03-28
JP2020511139A (ja) 2020-04-16
CA3056807A1 (en) 2018-09-20
MX2019011026A (es) 2020-12-10
AU2018235153A1 (en) 2019-10-31
BR112019019251A2 (pt) 2020-04-28
KR20190125481A (ko) 2019-11-06
CN110430893A (zh) 2019-11-08
US20220273782A1 (en) 2022-09-01
US20200085928A1 (en) 2020-03-19
JP2023021116A (ja) 2023-02-09
EP3595704A1 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201908567UA (en) Modified cyclic dinucleotide compounds
SG11201809064QA (en) Chimeric neurotoxins
SG11201811432WA (en) Rna for cancer therapy
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201909022PA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201408261UA (en) Syringe
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201809625RA (en) 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201408224SA (en) Novel ruthenium complexes, their use in the metathesis reactions, and a process for carrying out the metathesis reaction
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds